Barclays PLC Increases Eli Lilly and Co (LLY) Price Target to $90.00

Eli Lilly and Co (NYSE:LLY) had its target price upped by Barclays PLC from $85.00 to $90.00 in a research report sent to investors on Friday morning. The firm currently has an overweight rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Eli Lilly and from a hold rating to a buy rating and set a $86.00 target price on the stock in a research report on Tuesday, January 24th. Goldman Sachs Group Inc restated a buy rating and issued a $85.00 price objective (up previously from $82.00) on shares of Eli Lilly and in a research report on Wednesday, December 21st. Jefferies Group LLC boosted their price objective on shares of Eli Lilly and from $90.00 to $93.00 and gave the company a buy rating in a research report on Friday, January 20th. Citigroup Inc set a $100.00 price objective on shares of Eli Lilly and and gave the company a buy rating in a research report on Thursday, January 19th. Finally, Credit Suisse Group AG restated a buy rating on shares of Eli Lilly and in a research report on Tuesday, March 21st. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Eli Lilly and currently has an average rating of Buy and a consensus price target of $88.70.

Eli Lilly and (NYSE:LLY) traded up 0.055% during midday trading on Friday, reaching $81.985. The company’s stock had a trading volume of 2,291,667 shares. Eli Lilly and has a 12 month low of $64.18 and a 12 month high of $86.72. The stock has a 50-day moving average price of $84.25 and a 200 day moving average price of $77.93. The company has a market cap of $86.16 billion, a PE ratio of 31.777 and a beta of 0.30.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, January 31st. The company reported $0.95 EPS for the quarter, missing analysts’ consensus estimates of $0.98 by $0.03. The business earned $5.76 billion during the quarter, compared to analysts’ expectations of $5.54 billion. Eli Lilly and had a return on equity of 24.74% and a net margin of 12.90%. Eli Lilly and’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.78 EPS. Analysts expect that Eli Lilly and will post $4.11 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Barclays PLC Increases Eli Lilly and Co (LLY) Price Target to $90.00” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/04/21/eli-lilly-and-co-lly-pt-raised-to-90-00-at-barclays-plc-updated.html.

In other news, SVP Alfonso G. Zulueta sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $77.66, for a total value of $1,164,900.00. Following the transaction, the senior vice president now owns 45,583 shares in the company, valued at $3,539,975.78. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Derica W. Rice sold 11,162 shares of the company’s stock in a transaction that occurred on Friday, February 3rd. The stock was sold at an average price of $77.14, for a total transaction of $861,036.68. Following the completion of the transaction, the executive vice president now owns 58,443 shares in the company, valued at approximately $4,508,293.02. The disclosure for this sale can be found here. In the last quarter, insiders sold 688,162 shares of company stock worth $55,440,777. Insiders own 0.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of LLY. Tarbox Group Inc. increased its position in shares of Eli Lilly and by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock worth $124,000 after buying an additional 11 shares during the period. First Citizens Bank & Trust Co. increased its position in shares of Eli Lilly and by 0.3% in the third quarter. First Citizens Bank & Trust Co. now owns 5,920 shares of the company’s stock worth $476,000 after buying an additional 18 shares during the period. Strategic Financial Group LLC increased its position in shares of Eli Lilly and by 0.5% in the third quarter. Strategic Financial Group LLC now owns 3,449 shares of the company’s stock worth $277,000 after buying an additional 18 shares during the period. Alpha Windward LLC increased its position in shares of Eli Lilly and by 0.9% in the third quarter. Alpha Windward LLC now owns 2,133 shares of the company’s stock worth $171,000 after buying an additional 19 shares during the period. Finally, Enterprise Financial Services Corp increased its position in shares of Eli Lilly and by 0.9% in the third quarter. Enterprise Financial Services Corp now owns 2,150 shares of the company’s stock worth $173,000 after buying an additional 20 shares during the period. Institutional investors own 75.15% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply